title: Long-term outcome and toxicity after dose-intensified treatment with 131I-MIBG for advanced metastatic carcinoid tumors.
abstract: Reported experience with systemic (131)I-metaiodobenzylguanidine ((131)I-MIBG) therapy of neuroendocrine tumors comprises different dosing schemes. The aim of this study was to assess the long-term outcome and toxicity of treatment with 11.1 GBq (300 mCi) of (131)I-MIBG per cycle.
  
  
  METHODS
  We performed a retrospective review of 31 patients with advanced metastatic neuroendocrine tumors (20 with carcinoid tumors and 11 with other tumors) treated with (131)I-MIBG. Treatment outcome was analyzed for patients with carcinoid tumors (the most common tumors in this study), and toxicity was analyzed for the entire patient cohort (n = 31). Treatment comprised 11.1 GBq (300 mCi) per course and minimum intervals of 3 mo. The radiographic response was classified according to modified Response Evaluation Criteria in Solid Tumors. Toxicity was determined according to Common Terminology Criteria for Adverse Events (version 3.0) for all laboratory data at regular follow-up visits and during outpatient care, including complete blood counts and hepatic and renal function tests. Survival analysis was performed with the Kaplan-Meier curve method (log rank test; P < 0.05).
  
  
  RESULTS
  The radiographic responses in patients with carcinoid tumors comprised a minor response in 2 patients (10%), stable disease in 16 patients (80%; median time to progression, 34 mo), and progressive disease in 2 patients (10%). The symptomatic responses in patients with functioning carcinoid tumors comprised complete resolution in 3 of the 11 evaluable symptomatic patients (27%), partial resolution in 6 patients (55%), and no significant change in 11 patients. The median overall survival in patients with carcinoid tumors was 47 mo (95% confidence interval, 32-62), and the median progression-free survival was 34 mo (95% confidence interval, 13-55). Relevant treatment toxicities were confined to transient myelosuppression of grade 3 or 4 in 15.3% (leukopenia) and 7.6% (thrombocytopenia) of applied cycles and a suspected late adverse event (3% of patients), myelodysplastic syndrome, after a cumulative administered activity of 66.6 GBq. The most frequent nonhematologic side effect was mild nausea (grade 1 or 2), which was observed in 28% of administered cycles. No hepatic or renal toxicities were noted.
  
  
  CONCLUSIONS
  Dose-intensified treatment with (131)I-MIBG at a fixed dose of 11.1 GBq (300 mCi) per cycle is safe and offers effective palliation of symptoms and disease stabilization in patients with advanced carcinoid tumors. The favorable survival and limited toxicity suggest that high cycle activities are suitable and that this modality may be used for targeted carcinoid treatment--either as an alternative or as an adjunct to other existing therapeutic options.
authors.affiliation: Department of Nuclear Medicine, University Hospital, Bonn, Germany.
authors.forename: Samer
authors.initials: S
authors.lastname: Ezziddin
authors.forename: Amir
authors.initials: A
authors.lastname: Sabet
authors.forename: Timur
authors.initials: T
authors.lastname: Logvinski
authors.forename: Khaled
authors.initials: K
authors.lastname: Alkawaldeh
authors.forename: Charlotte J
authors.initials: CJ
authors.lastname: Yong-Hing
authors.forename: Hojjat
authors.initials: H
authors.lastname: Ahmadzadehfar
authors.forename: Frank
authors.initials: F
authors.lastname: Grünwald
authors.forename: Hans-Jürgen
authors.initials: HJ
authors.lastname: Biersack
mesh_terms: D019797:3-Iodobenzylguanidine / Q000009:adverse effects* / Q000627:therapeutic use*; D000328:Adult; D000368:Aged; D002276:Carcinoid Tumor / Q000473:pathology* / Q000532:radiotherapy*; D015331:Cohort Studies; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis; D011829:Radiation Dosage; D011879:Radiotherapy Dosage; D012189:Retrospective Studies; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D019797:3-Iodobenzylguanidine
keywords: 131I-MIBG therapy; carcinoid tumors; neuroendocrine tumors; oncology; radionuclide therapy; targeted radiotherapy